Last updated 2026-08-06
- Raised $165M Series A led by Dexcel Pharma, Dec 2025
- Raised $150M Seed Extension, Jul 2025
- Raised $45M Series B led by Qumra Capital, Aug 2026
Total raised
$415.0M
Stage
—
Founded
2008
Headcount
—
HQ
Jerusalem, Israel
Sector
Life Sciences
About
SyndromeX focuses on developing drugs for the metabolic syndrome and its discrete diseases. The company has developed the MEDICA platform, consisting of drugs that target the metabolic syndrome and its drivers (AMPK, mitochondrial PTP, HNF4alpha, FoxO1, mTORC1 and STAT3). MEDICA drugs target metabolic syndrome and its component diseases, namely diabetes type 2, dyslipidemia, and obesity.
Funding history · 5 rounds · $415.0M total
2026-08
B Round
$45.0M
★ Qumra CapitalSanofiGC VenturesPitango HealthTechNewHealth VenturesShoni Top VenturesEsplanade VenturesAccenture VenturesArtofin Venture Capital Fund L.P.Bertelsmann Healthcare Investments (BHI)
2025-12
A Round
$165.0M
★ Dexcel Pharma★ Third Rock VenturesQVTPictetGV (Google Ventures)Bain Capital Life Sciences
2025-07
Seed Extension
$150.0M
2004-10
Seed Extension
Undisclosed
2002-10
Seed
$55.0M
★ OurCrowd★ Shavit Capital★ Technology Transfer Company
Q&A
- What is SyndromeX's primary focus?
- SyndromeX focuses on developing drugs for metabolic syndrome and its related diseases, including diabetes type 2, dyslipidemia, and obesity.
- What is the core technology developed by SyndromeX?
- SyndromeX has developed the MEDICA platform, which consists of drugs targeting metabolic syndrome and its drivers such as AMPK, mitochondrial PTP, HNF4alpha, FoxO1, mTORC1, and STAT3.
- When was SyndromeX founded?
- SyndromeX was founded in 2008.
- Who are the lead investors in SyndromeX's Seed round?
- SyndromeX's Seed round, which closed in October 2002, included Shavit Capital and OurCrowd as lead investors.
- Which investors participated in SyndromeX's Series A round?
- SyndromeX completed its Series A round in December 2025, with Dexcel Pharma and Third Rock Ventures as lead investors.
- Who led SyndromeX's Series B funding round?
- In August 2026, SyndromeX closed a Series B round of $45,000,000, led by Qumra Capital.
- Who is the founder of SyndromeX?
- Prof. Jacob Bar-Tana is the founder of SyndromeX, appointed in October 2002.
- Who is the CEO of SyndromeX?
- Mr. Uri Litvin serves as the CEO of SyndromeX.
Team · 2
Prof. Jacob Bar-Tana
Founder · Founder
Mr. Uri Litvin
CEO
Sectors & technology
Primary sector
Life Sciences
Target customers
Business model
B2C
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Legal name | SyndromeX |
|---|---|
| Founded | 2008 |
Radar intelligence
Patents
| EPO | 7 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512504978 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1997-07-09 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | התלתן 2 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-12 | דו~ח שנתי |